OAB-001 Potentiating T cell activity against multiple myeloma through SUMOylation inhibition Li Du1, Dennis Awuah1, Wei Liu2, En
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer
Light Chain Myeloma: Symptoms, Treatment, Outlook, More
Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
Inflammation and tumor progression: signaling pathways and targeted intervention | Signal Transduction and Targeted Therapy
OAB-001 Potentiating T cell activity against multiple myeloma through SUMOylation inhibition Li Du1, Dennis Awuah1, Wei Liu2, En
Multiple myeloma - Wikipedia
Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
ICD-10 International statistical classification of diseases and related health problems
PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports
ICD10CM Index 2010
Vol 80. Num 3 - Galicia Clínica
ICD-10 Code for Multiple myeloma- C90.0- Codify by AAPC
Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML
Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data - Clinical Lymphoma, Myeloma and Leukemia
Part 2e. Instruction Manual- ICD-10-Volume 3
Abstract - 2020 - American Journal of Hematology - Wiley Online Library
Types of Multiple Myeloma | International Myeloma Foundation